SCHEMBL5115720

SCHEMBL5115720

FC(F)(F)c1cccc(-c2ccc(N3CCN4CCCC3CCC4)nc2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 3/20 0.42
HDAC6 Q9UBN7 3/20 0.42
MGLL Q99685 1/20 0.42
KDM2B Q8NHM5 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GRIN2B Q13224 6/20 0.39
CNR2 P34972 5/20 0.39
GRIN1 Q05586 5/20 0.39
CNR1 P21554 1/20 0.38
SYK P43405 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5108182 0.98 HDAC8 (0.41) HDAC8HDAC6MGLLKDM2BMEN1
SCHEMBL5110873 0.94 HDAC8 (0.41) HDAC8HDAC6MGLLKDM2BMEN1
SCHEMBL5115818 0.87 HDAC8 (0.44) HDAC8HDAC6MGLLALDH1A1GAA
SCHEMBL5110600 0.87 HDAC8 (0.42) HDAC8HDAC6MGLLKDM2BGRIN2B
SCHEMBL5112387 0.86 GRM5 (0.41) KDM2B
Hydrochloric Acid SCHEMBL5108802 0.86 HDAC8 (0.42) HDAC8HDAC6MGLLKDM2BGRIN2B
SCHEMBL5113901 0.84 HTR3A (0.41) KDM2B
SCHEMBL5123021 0.83 CNR2 (0.53) MGLLKDM2BKMT2ACNR2
SCHEMBL5112996 0.81 CNR2 (0.51) MGLLKDM2BKMT2ACNR2
SCHEMBL5108601 0.80 CYP11B1 (0.43) MGLLKDM2BMEN1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC 2004-06-03 US claimed
US-7442694-B2 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC (US) 2008-10-28 US disclosed
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders DBH, CHRNA6, DDT HDAC8 1608/4885HDAC6 258/4885MGLL 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.